![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
Posts
The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: https://bit.ly/pre1702-study #LCSM #RWD #RWE
Do you have an aggressive B-cell #Lymphoma that has either come back or persisted after initial therapy? If so, you may be eligible to participate in #ClinicalTrial EA4231. More info here: https://bit.ly/EA4231 #lymsm
EA8192, led by @JCensits and @PGrivasMDPhD, is a phase II/III #clinicaltrial of durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. For more: https://bit.ly/ea8192-trial #blcsm
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
37
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
